Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Foghorn Therapeutics (FHTX) Gross Profit: 2019-2024

Historic Gross Profit for Foghorn Therapeutics (FHTX) over the last 6 years, with Dec 2024 value amounting to $22.6 million.

  • Foghorn Therapeutics' Gross Profit rose 4.42% to $8.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.5 million, marking a year-over-year decrease of 3.91%. This contributed to the annual value of $22.6 million for FY2024, which is 33.83% down from last year.
  • Latest data reveals that Foghorn Therapeutics reported Gross Profit of $22.6 million as of FY2024, which was down 33.83% from $34.2 million recorded in FY2023.
  • Foghorn Therapeutics' Gross Profit's 5-year high stood at $34.2 million during FY2023, with a 5-year trough of $430,000 in FY2020.
  • Moreover, its 3-year median value for Gross Profit was $22.6 million (2024), whereas its average is $25.3 million.
  • Per our database at Business Quant, Foghorn Therapeutics' Gross Profit soared by 1,357.77% in 2022 and then tumbled by 33.83% in 2024.
  • Yearly analysis of 5 years shows Foghorn Therapeutics' Gross Profit stood at $430,000 in 2020, then surged by 206.74% to $1.3 million in 2021, then skyrocketed by 1,357.77% to $19.2 million in 2022, then spiked by 77.63% to $34.2 million in 2023, then plummeted by 33.83% to $22.6 million in 2024.